Drawing a bead on lymphangiogenesis Tim Fulmer doi:10.1038/scibx.2012.970 A team of German researchers has developed a high throughput assay to identify compounds that block lymphangiogenesis, a process that promotes the progression and metastasis of solid tumors. Some of the top hits were statins, which the researchers plan to test in preclinical cancer models. Full Text | PDF
Stabilizing RyR2 Lauren Martz doi:10.1038/scibx.2012.971 Two separate teams have found that preventing calcium ion leak from ryanodine receptors could help treat CNS disorders. Based on these findings, Armgo is developing brain-penetrating versions of its ryanodine receptor–stabilizing compounds for neurological indications. Full Text | PDF
ASIRTaining a Parkinson's disease target Lev Osherovich doi:10.1038/scibx.2012.972 A Tufts University team has compelling evidence that reducing sirtuin 2 activity could be beneficial in Parkinson's disease. The findings argue for developing brain-penetrating SIRT2 inhibitors. Full Text | PDF
Strategic synergy Tracey Baas doi:10.1038/scibx.2012.973 NYU researchers have shown that the induction of NKG2D ligands contributes to the synergy of radiotherapy with an anti–CTLA-4 mAb. The findings could be used to identify patients most likely to respond to anti–CTLA-4 treatment and to help establish which radiation regimens would enhance the treatment. Full Text | PDF
Signal regulatory protein-α (SIRPA) doi:10.1038/scibx.2012.975 Patient sample and mouse studies suggest disrupting the interaction between SIRPA and CD47 could help treat AML. Full Text | PDF
Cathepsin B doi:10.1038/scibx.2012.976 In vitro and mouse studies have identified a bone-targeting doxorubicin prodrug that could help treat bone metastasis. Full Text | PDF
β-Catenin (CTNNB1); B cell CLL lymphoma 9 (BCL9); wingless-type MMTV integration site (WNT) doi:10.1038/scibx.2012.977 Mouse studies suggest disrupting the interaction between CTNNB1 and the WNT pathway coactivator BCL9 could help treat WNT-driven cancers. Full Text | PDF
CXC chemokine receptor 2 (CXCR2; IL8RB) doi:10.1038/scibx.2012.978 Mouse studies suggest CXCR2 antagonists could help treat cancer. Full Text | PDF
Ubiquitin specific peptidase 7 (USP7; HAUSP) doi:10.1038/scibx.2012.979 In vitro and mouse studies suggest the USP7 inhibitor P5091 could help treat MM. Full Text | PDF
Matrix metalloproteinase 2 (MMP2); MMP9 doi:10.1038/scibx.2012.980 In vitro and mouse studies identified the endohedral metallofullerenol Gd@C82(OH)22 as an MMP inhibitor that could help treat pancreatic cancer. Full Text | PDF
Protein kinase Cβ (PRKCB) doi:10.1038/scibx.2012.981 In vitro and mouse studies suggest PRKCB inhibitors could help treat Ewing's sarcoma. Full Text | PDF
NEDD8 activating enzyme (NAE) doi:10.1038/scibx.2012.982 Cell culture studies suggest inhibiting neddylation with NAE inhibitors could help treat inflammation. Full Text | PDF
Bromodomain containing 4 (BRD4) doi:10.1038/scibx.2012.983 Full Text | PDF
Smoothened (SMO) doi:10.1038/scibx.2012.987 Mouse and patient studies suggest inhibiting SMO to reduce hedgehog pathway signaling could help prevent or treat sclerodermatous GvHD. Full Text | PDF
Peroxisome proliferation–activated receptor-γ (PPARG; PPARγ) doi:10.1038/scibx.2012.988 Cell culture studies identified oxygenated polyketide-based PPARγ activators from the Plakinastrella mamillaris sponge that could help treat diabetes and inflammatory diseases. Full Text | PDF
High throughput screen for inhibitors of lymphangiogenesis doi:10.1038/scibx.2012.989 A high throughput, cell-based assay could be useful for identifying inhibitors of tumor lymphangiogenesis, which is the aberrant growth of the lymphatic system that can drive metastasis of solid cancers. Full Text | PDF
Silicon-based peptide arrays for mapping antibody-histone interactions doi:10.1038/scibx.2012.990 A silicon-based peptide array for mapping the interactions of antibodies with differentially modified histones could be used to identify patients who will respond to therapy. Full Text | PDF
Cell line–based culture system for generating human bocavirus doi:10.1038/scibx.2012.991 A cell line that generates human bocavirus 1 could be useful for developing vaccines and models of bocavirus infection. Full Text | PDF
Epigenetic markers to predict risk of long-term liver damage doi:10.1038/scibx.2012.992 Rat studies suggest heritable epigenetic modifications induced by liver fibrosis could help predict long-term liver damage susceptibility in offspring. Full Text | PDF
Killer cell lectin-like receptor subfamily K member 1 (KLRK1; CD314; NKG2D) ligands as markers to predict response to anti–CTLA-4 (CD152) therapies and guide selection of radiation therapy regimens doi:10.1038/scibx.2012.993 Mouse studies suggest levels of NKG2D ligands could be used as a marker to predict patient responsiveness to anti–CTLA-4 therapies and help guide selection of radiation therapy regimens. Full Text | PDF
Mutations in the extracellular domain of HER2 (EGFR2; ErbB2; neu) as markers of susceptibility to ErbB2 inhibitors doi:10.1038/scibx.2012.994 In vitro studies identified oncogenic mutations in the ErbB2 extracellular domain and suggest ErbB2 inhibitors could help treat cancers that harbor such mutations. Full Text | PDF
You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant)
Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA
Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston
Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS.
No comments:
Post a Comment